Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Ipamorelin crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 243 certificate records for Ipamorelin products, from 81 vendors 153 reference a report on the testing laboratory's own system · 116 have a laboratory lookup that answered when last checked · 224 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Medium

No FDA label signal · 3 trials · 50 PubMed results

Promising

Research evidence

Ipamorelin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Ipamorelin has 2 name-matched clinical trials (highest phase: Phase 2) and 50 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data

Phase 2

Trial quality

Large RCT

Outcomes

Surrogate / early

Replication

Multiple trials

Literature

High-impact

PHASE2 · Randomized Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function PHASE2 · Randomized Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus European Journal of Endocrinology · 99 citations Ipamorelin, the first selective growth hormone secretagogue Drug Testing and Analysis · 49 citations Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP‐1, GHRP‐2, GHRP‐6, Hexarelin, and Ipamorelin Journal of Medicinal Chemistry · 34 citations A New Series of Highly Potent Growth Hormone-Releasing Peptides Derived from Ipamorelin Journal Article Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What ipamorelin is

Ipamorelin is a growth hormone secretagogue that is usually discussed as a ghrelin-mimetic peptide. It commonly appears in the same conversations as CJC-1295 because the two are frequently described together in growth-hormone optimization stacks.

Why it matters

It is one of the most recognizable non-approved entries in the growth-hormone peptide category, so it helps anchor the library for readers trying to understand that corner of the market.

Regulatory context

Ipamorelin is not FDA-approved as a peptide medicine in the United States. On PeptideBenchmark it is categorized as research-market, not approved therapy.

Practical reading note

If a page talks about ipamorelin as if it were standard wellness medicine, that is usually a sign the regulatory context is being blurred.